Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Hangzhou Tigermed Consulting expects quarterly results for end of June, EPS forecast sharply lower

Hangzhou Tigermed Consulting will publish results on 28 August 2026 for the quarter ended 30 June 2026. Two analysts forecast earnings per share of 0.143 CNY, a decline of 45% from 0.260 CNY in the same quarter last year. Analysts estimate quarterly revenue at an average of 1.89 billion CNY (+12.09% year‑on‑year). For the fiscal year, median estimates are 1.00 CNY earnings per share (7 analysts) and 7.72 billion CNY revenue (5 analysts). » More on finanzen.net
Hangzhou Tigermed Consulting: quarterly loss per share, annual profit rises

Hangzhou Tigermed Consulting reported for the quarter ended 31.12.2025 a loss per share of -0.15 CNY (previous year: -0.47 CNY) on revenue of 1.81 billion CNY (previous year: 1.54 billion CNY). For the full year, earnings per share were 1.04 CNY versus 0.47 CNY in the prior year. Annual revenue rose 3.78 percent to 6.83 billion CNY (previous year: 6.58 billion CNY). » More on finanzen.net
Hangzhou Tigermed Consulting improves annual profit and slightly increases revenue

In the quarter ended 31 Dec 2025, Hangzhou Tigermed Consulting reported a loss of HKD 0.17 per share compared with a loss of HKD 0.51 in the year-earlier quarter, on revenue of HKD 1.98 billion (prior year HKD 1.66 billion). For the full year, earnings per share were HKD 1.13, after HKD 0.51 in the previous year. Annual revenue rose 3.81 percent to HKD 7.41 billion. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, HANGZHOU TIGERMED CO. H 1 has already paid €0.0162 in dividends. The last payout was in July.

Financials

In the last quarter, HANGZHOU TIGERMED CO. H 1 had revenue of €274.41m and net profit of €18.58m

(EUR)	September 2026	YoY
Revenue	274.41m	29.16%
Gross profit	74.19m	27.15%
Net profit	18.58m	75.63%
EBITDA	94.51m	10.83%

Fundamentals

Metric	Value
Market capitalization	€5.24bn
Number of shares	1.21bn
52-week high/low	€6.48 - €3.20
Dividend yield	0.37%
Dividends TTM	€0.0162
Beta	0.34
P/E ratio	-103.48
PEG ratio	0.61
P/B ratio	2.11
P/S ratio	4.79

Company profile

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.